title: Treatment of Melanoma CNS Metastases.
abstract: The discovery of the BRAFV600 mutation and the development of targeted therapies directed against this mutation as well as effective immunotherapies with durable benefits have revolutionized the treatment of patients with melanoma. Nonetheless, the frequent occurrence of brain metastases in patients with advanced melanoma represents a significant obstacle to long-term, high quality survival. The application of stereotactic radiation therapy has provided an opportunity to control brain metastases in the majority of patients with metastatic melanoma reducing the impact of these lesions on morbidity and mortality and enabling patients to receive and potentially benefit from these novel systemic treatments. Encouragingly, several of these novel new therapies have shown antitumor activity against CNS metastases that approach that seen against extracranial disease. As a consequence, several effective treatment options are now available for patients with melanoma brain metastases. With these tools in hand, it is anticipated that further investigation into the optimal sequence and/or combination of systemic therapies and local therapies along with multidisciplinary team practice will continue to improve the outcome of patients with this previously life-limiting disease complication.
authors.affiliation: Georgetown Lombardi Comprehensive Cancer Center, Washington, D.C., USA.
authors.forename: Sekwon
authors.initials: S
authors.lastname: Jang
authors.affiliation: Georgetown Lombardi Comprehensive Cancer Center, Washington, D.C., USA. mba41@georgetown.edu.
authors.forename: Michael B
authors.initials: MB
authors.lastname: Atkins
mesh_terms: D001932:Brain Neoplasms / Q000556:secondary* / Q000628:therapy*; D006801:Humans; D007167:Immunotherapy; D008545:Melanoma / Q000556:secondary* / Q000628:therapy*; D016634:Radiosurgery
keywords: Braf inhibitor therapy; Immunotherapy; Melanoma brain metastases; Stereotactic radiosurgery